Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fordadistrogene movaparvovec - Pfizer

Next Previous
Search
Drug Profile

Fordadistrogene movaparvovec - Pfizer

Alternative Names: BMB-D-001; PF 06939926

Latest Information Update: 17 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bamboo Therapeutics
  • Developer Pfizer
  • Class Gene therapies
  • Mechanism of Action Dystrophin replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 12 Jun 2024 Efficacy and adverse events data from the phase III CIFFREO trial in Duchenne muscular dystrophy released by Pfizer
  • 01 May 2024 Discontinued - Phase-III for Duchenne muscular dystrophy (In children) in Russia, Switzerland, Taiwan, USA, South Korea, Japan, France, Canada, Belgium, United Kingdom, Italy, Spain, Australia, Germany, Israel (IV) (Pfizer pipeline July 2024)
  • 14 Nov 2023 US FDA granted Rare Pediatric Disease for Duchenne muscular dystrophy, prior to November 2023 (Pfizer website, November 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top